首页 | 本学科首页   官方微博 | 高级检索  
   检索      


<Emphasis Type="Italic">PIK3CA</Emphasis> mutations in <Emphasis Type="Italic">KRAS</Emphasis> and <Emphasis Type="Italic">BRAF</Emphasis> wild type colorectal cancer patients. A study of Spanish population
Authors:Email author" target="_blank">Marta?Herreros-VillanuevaEmail author  Noemí?Gomez-Manero  Pilar?Mu?iz  Carlos?García-Girón  Maria?Jesús?Coma del Corral
Institution:1.Unidad de Investigación,Hospital General Yagüe,Burgos,Spain;2.Servicio de Medicina Interna,Hospital General Yagüe,Burgos,Spain;3.Departamento de Bioquímica,Universidad de Burgos,Burgos,Spain;4.Servicio de Oncología,Hospital General Yagüe,Burgos,Spain
Abstract:The objective of the work was to study PIK3CA mutations in wild type KRAS and BRAF colorectal cancer. Clinicopathological data and paraffin-embedded specimens were collected on 73 patients who underwent colorectal resections at General Yagüe Hospital in Burgos. KRAS, BRAF and PIK3CA status were analyzed by real-time PCR in all patients. PIK3CA mutations were present in 8.22% of wild type KRAS and BRAF colorectal cancers. The most frequent mutation is E545K/D in exon 9 which represents 83.3% of all mutations. By contrast, we did not found any tumour harbouring H1047R mutation in exon 20. Among the patients who undergo a curative resection of colorectal cancer, PIK3CA mutation is present in an important percentage of KRAS and BRAF wild type tumours. PIK3CA mutation may be considered as it could be a hypothetic reason to be not responder to anti-EGFR antibodies.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号